Xyloketal-derived small molecules show protective effect by decreasing mutant huntingtin protein aggregates in Caenorhabditis elegans model of huntington’s disease

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 1443-1451

  Zeng, Yixuan ^a,b   Guo, Wenyuan ^a   Xu, Guangqing ^c   Wang, Qinmei ^d   Feng, Luyang ^a,b   Long, Simei ^a   Liang, Fengyin ^a   Huang, Yi ^a   Lu, Xilin ^a   Li, Shichang ^a   Zhou, Jiebin ^a   Burgunder, Jean Marc ^e   Pang, Jiyan ^a   Pei, Zhong ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Chinese Huntington s Disease Network   (China)

^c First Affiliated Hospital   (China)

^d BEIJING HOSPITAL   (China)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

Caenorhabditis elegans; Huntington s disease; Molecular target; Mutant huntingtin; Protein misfolding; Xyloketal derivatives

Indexed keywords

HUNTINGTIN; NATURAL PRODUCT; UNCLASSIFIED DRUG; XYLOKETAL B DERIVATIVE; NEUROPROTECTIVE AGENT; PROTEIN AGGREGATE; PYRAN DERIVATIVE; XYLOKETAL B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CAENORHABDITIS ELEGANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUNTINGTON CHOREA; LIGAND BINDING; MOLECULAR DOCKING; NEUROPROTECTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; SYNTHESIS;

ANIMALS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MOLECULAR DOCKING SIMULATION; NEUROPROTECTIVE AGENTS; PROTEIN AGGREGATES; PYRANS; SMALL MOLECULE LIBRARIES;

EID: 84964413635     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S94666     Document Type: Article

References (46)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72:971–983.
2. Hoffner G, Island ML, Djian P. Purification of neuronal inclusions of patients with Huntington’s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J Neurochem. 2005;95:125–136.
3. Schilling G, Sharp AH, Loev SJ, et al. Expression of the Huntington’s disease (IT15) protein product in HD patients. Hum Mol Genet. 1995;4:1365–1371.
4. Hoffner G, Djian P. Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion. Brain Sci. 2014;4:91–122.
5. Qin ZH, Gu ZL. Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol Sin. 2004;25(10):1243–1249.
6. Chánez-Cárdenas ME, Vázquez-Contreras E. The aggregation of Huntingtin and α-Synuclein. J Biophys. 2012;2012:606172.
7. Swarnkar S, Chen Y, Pryor WM, Shahani N, Page DT, Subramaniam S. Ectopic expression of the striatal-enrich GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntinton’s diseae. Neurobiol Dis. 2015;82:66–77.
8. Lazarev VF, Benken KA, Semenyuk PI, et al. GAPDH binders as potential drugs for the therapy of polyglutamine disease, design of a new screening assay. FEBS Lett. 2015;589(5):581–587.
9. Lin Y, Wu X, Feng S, et al. Five unique compounds: xyloketals from mangrove fungus Xylaria sp. from the South China Sea coast. J Org Chem. 2001;66:6252–6256.
10. Long SM, Liang FY, Wu Q, et al. Identification of marine neuroactive molecules in behaviour-based screens in the larval zebrafish. Mar Drugs. 2014;12:3307–3322.
11. Li S, Shen C, Guo W, et al. Synthesis and neuroprotective action of xyloketal derivatives in Parkinson’s disease models. Mar Drugs. 2013;11:5159–5189.
12. Xiao AJ, Chen W, Xu B, et al. Sun. Marine compound xyloketal B reduces neonatal hypoxic-ischemic brain injury. Mar Drugs. 2015;13:29–47.
13. Su J, Chang C, Xiang Q, et al. Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study. Drug Des Devel Ther. 2014;8:2555–2602.
14. Pettigrew JD, Cadieux JA, So SS, Wilson PD. Phenylboronic acid mediated triple condensation reactions of phloroglucinol and unsaturated carbonyl compounds. Org Lett. 2005;7:467–470.
15. Li J, Le W. Modeling neurodegenerative diseases in Caenorhabditis elegans. Exp Neurol. 2013;250:94–103.
16. Parker JA, Holbert S, Lambert E, Abderrahmane S, Neri C. Genetic and pharmacological suppression of polyglutamine-dependent neuronal dysfunction in Caenorhabditis elegans. J Mol Neurosci. 2004;23:61–68.
17. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369–384.
18. Gama Sosa MA, De Gasperi R, Elder GA. Modeling human neurodegenerative diseases in transgenic systems. Hum Genet. 2012;131:535–563.
19. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A. 1999;96:179–184.
20. Holbert S, Denghien I, Kiechle T, et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington’s disease pathogenesis. Proc Natl Acad Sci U S A. 2001;98:1811–1816.
21. Gohil VM, Offner N, Walker JA, et al. Meclizine is neuroprotective in models of Huntington’s disease. Hum Mol Gen. 2011;20: 294–300.
22. Steffan JS, Thompson LM. Targeting aggregation in the development of therapeutics for the treatment of Huntington’s disease and other polyglutamine repeat diseases. Expert Opin Ther Targets. 2003;7:201–213.
23. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC. Identification of potential therapeutic drugs for Huntington’s disease using Caenorhabditis elegans. PloS One. 2007;2:e504.
24. Wang H, Lim PJ, Yin C, Rieckher M, Vogel BE, Monteiro MJ. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington’s disease by ubiquilin. Hum Mol Gen. 2006;15:1025–1041.
25. Waterston RH, Epstein HF, Brenner S. Paramyosin of Caenorhabditis elegans. J Mol Biol. 1974;90:285–290.
26. Satyal SH, Schmidt E, Kitagawa K, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2000;97:5750–5755.
27. Mariol MC, Walter L, Bellemin S, Gieseler K. A Rapid Protocol for integrating extrachromosomal arrays with high transmission rate into the C. elegans genome. J Vis Exp. 2013;82:50773.
28. Stiernagle T, Ceenorhabditis Genetic Center. Maintenance of C. elegans. Worm book. 2006:1–11. (PMID: 18050451 in pubmed).
29. Wang X, Yang C, Chai J, Shi Y, Xue D. Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science. 2002; 298:1587–1592.
30. Kahlem P, Green H, Djian P. Transglutaminase action imitates Huntington’s disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell. 1998;1:595–601.
31. Iuchi S, Hoffner G, Verbeke P, Djian P, Green H. Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci U S A. 2003;100:2409–2414.
32. Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington’s disease protein and discrimination of the normal and mutated form. Nat Genet. 1995;10:104–110.
33. Andre W, Sandt C, Dumas P, Djian P, Hoffner G. Structure of inclusions of Huntington’s disease brain revealed by synchrotron infrared microspectroscopy: polymorphism and relevance to cytotoxicity. Anal Chem. 2013;85:3765–3773.
34. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington’s disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis. 1998;4:387–397.
35. Liang V, Ullrich M, Lam H, et al. Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteome. Cell Mol Life Sci. 2013;71:3339–3361.
36. Kim M. Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues. Prion. 2013;7:221–228.
37. Davranche A, Aviolat H, Zeder-Lutz G, et al. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. Hum Mol Gen. 2011;20:2795–2806.
38. Gao T, Collins RE, Horton JR, et al. The ankyrin repeat domain of Huntingtin interacting protein 14 contains a surface aromatic cage, a potential site for methyl-lysine binding. Proteins. 2009;76:772–777.
39. Gupta S, Misra G, Pant MC, Seth PK. Prediction of a new surface binding pocket and evaluation of inhibitors against huntingtin interacting protein 14: an insight using docking studies. J Mol Model. 2011;17:3047–3056.
40. Perutz MF, Staden R, Moens L, De Baere I. Polar zippers. Curr Biol. 1993;3:249–253.
41. De Baere I, Liu L, Moens L, et al. Polar zipper sequence in the high-affinity hemoglobin of Ascaris suum: amino acid sequence and structural interpretation. Proc Natl Acad Sci U S A. 1992;89:4638–4642.
42. Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natil Acad Sci U S A. 1994;91:5355–5358.
43. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493–506.
44. Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I. Secondary structure of Huntingtin amino-terminal region. Structure. 2009;17:1205–1212.
45. Darnell G, Orgel JP, Pahl R, Meredith SC. Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol Biol. 2007;374:688–704.
46. Nakano M, Watanabe H, Starikov EB, Rothstein SM, Tanaka S. Mutation effects on structural stability of polyglutamine peptides by molecular dynamics simulation. Interdiscip Sci. 2009;1:21–29.